



AUG 07 2008

PTO/SB/08b (01-08)

Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
used in a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete If Known	
Application Number	10/714,449-Conf. #9366
Filing Date	November 17, 2003
First Named Inventor	Laguens
Art Unit	1633
Examiner Name	S. Kaushal
Attorney Docket Number	42597-193226

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Kastrup et al., "Direct Intramyocardial Plasmid Vascular Endothelial Growth Factor-A ₁₆₅ Gene Therapy in Patients with Stable Severe Angina Pectoris", JACC, 45(7), 2005, pp. 982-988	
	C2	Vera Janavel et al., "Plasmid-mediated VEGF gene transfer induced cardiomyogenesis and reduces myocardial infarct size in sheep", Gene Therapy, 2006, pp. 1-10	
	C3	Stewart/Cannon, "NORTHERN: A Prospective, Randomized, Double Blind, Placebo-Controlled Evaluation of Intramyocardian VEGF-165 Plasmid Gene Therapy in Patients with Refractory Angina", Transcatheter Cardiovascular Therapeutics conference, Cardiovascular Research Foundation, October 23, 2007, Abstract	
	C4	Lekas et al., Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation", Therapeutic neovascularization for ischaemic vascular disease, Current Opinion in Cardiology 21, pp. 376-383	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--